<DOC>
	<DOC>NCT01276275</DOC>
	<brief_summary>The purpose of the study is to describe patient characteristics and drug usage among patients that are prescribed ticagrelor for the first time and to compare them with patients who are prescribed clopidogrel and prasugrel for the first time. A further purpose is to ascertain and estimate the crude incidence rate of bleeding, arrhythmias, heart failure, acute renal failure, acute liver failure, dyspnoea and gout among new users in the three cohorts of ticagrelor, clopidogrel and prasugrel.</brief_summary>
	<brief_title>Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Dyspnea</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Liver Failure, Acute</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>First time users of ticagrelor, clopidogrel and prasugrel, respectively Individuals with more than one of above three antiplatelet drugs dispensed the same day</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Acute coronary syndrome, thienopyridine, epidemiology</keyword>
</DOC>